標靶治療藥品之皮膚毒性預防及照護指引

Clinical Practice Guideline: Prevention and Management of Targeted Therapy Related Skin Toxicities

10.3966/168395442015121503005

張黎露(Li-Lu Chang)；朱家瑜(Chia-Yu Chu)；姜紹青(Shao-Chin Chiang)；許麗珠(Li-Chu Sheu)；黃國埕(Kuo-Cheng Huang)；周文珊(Wen-Shan Chou)；張美娟(Mei-Chuan Chang)；侯秀香(Hsiu-Hsiang Hou)

標靶治療 ； 癌症病人 ； 皮膚毒性 ； 照護指引 ； Targeted Therapy ； Cancer Patient ； Skin Toxicities ； Practice Guideline

腫瘤護理雜誌

15卷增訂刊（2015 / 12 / 01）

47 - 80

繁體中文

標靶治療藥品已經成為有效的癌症治療模式之一，相對於傳統的化療，標靶藥品雖可專一且直接地針對癌細胞生長途徑加以破壞以減少正常細胞傷害和降低治療的副作用，但根據臨床研究顯示，不同型態的標靶藥品治療，仍會伴隨不同程度的副作用，且與傳統細胞毒性藥品所引起的副作用型態完全不同。由於標靶藥品需要長期使用，有效預防與控制副作用是照護癌症病人的重要課題。本指引針對標靶治療引起的皮膚毒性包括丘疹膿疱疹、甲溝炎、毛髮改變、手足皮膚反應、皮膚乾燥、皮膚癢、皮膚龜裂和光敏感反應等進行系統性的文獻搜尋和評讀，同時彙整國內專家與未來指引使用者之意見，根據本國可用之醫療資源，最後形成可行之照護建議。本文可做為病人在接受標靶藥品治療引起之皮膚副作用之照護指引，幫助臨床專業人員的臨床決策，以提供病人最合適的照護。

Targeted therapy is well established as an effective treatment for cancers. Patients receiving certain types of targeted therapy, may develop varied type of dermatologic toxicities. Although these skin reactions are rarely severe, they often cause major discomfort that sometimes leads to treatment interruption. Prevention and management of target therapy-induced skin toxicities is crucial to ensure cancer patientʼs quality of life and treatment outcome. This guideline was developed based on systematic review of literature, appraisal of the evidences, and summary of recommendations for practice by expert committee. This guideline focuses on the following skin toxicities: papulopustular rash, paronychia, hair changes, hand-foot skin reaction, xerosis, pruritus, fissures, and photosensitivity. The guideline with comprehensive prevention and management recommendations are intended to assist the healthcare professionals in their decision-making for optimal quality of individualized patient care.

1. Agero, A. L.(2006).Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.J. Am. Acad. Dermatol,55,657-670.
2. Balagula, Y.,Lacouture, M. E.,Cotliar, J. A(2010).Dermatologic toxicities of targeted anticancer therapies.J. Support,8,149-161.
3. Belum, V. R.,Fischer, A.,Choi, J. N.,Lacouture, M. E.(2013).Dermatological adverse events from BRAF inhibitors: a growing problem.Curr. Oncol. Rep,15,249-259.
4. Bracarda, S.(2012).Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.Crit. Rev. Oncol. Hematol,82,378-386.
5. Burtness, B.(2009).NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.J. Natl. Compr. Canc. Netw,7(Suppl 1),S5-S21+S22-24.
6. Curry, J. L.(2014).Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.Int. J. Dermatol,53,376-384.
7. Degen, A.(2010).The hand-foot-syndrome associated with medical tumor therapy - classification and management.Journal of the German Society of Dermatology,8,652-661.
8. Dreno, B.(2013).Algorithm for dermocosmetic use in the management of cutaneous sideeffects associated with targeted therapy in oncology.J. Eur. Acad. Dermatol. Venereol,27,1071-1080.
9. Drucker, A. M.,Rosen, C. F.(2011).Drug-induced photosensitivity: culprit drugs, management and prevention.Drug Saf,34,821-837.
10. Eaby, B.,Culkin, A.,Lacouture, M. E.(2008).An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.Clin. J. Oncol. Nurs.,12,283-290.
11. Ensslin, C. J.,Rosen, A. C.,Wu, S.,Lacouture, M. E.(2013).Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.J. Am. Acad. Dermatol,69,708-720.
12. European Society for Medical Oncology. Skin Changes - Fissures, (2009).
13. European Society for Medical Oncology. EGFRI-Related Skin Toxicity-Prophylactic Management, (2009).
14. Gomez, P.,Lacouture, M. E.(2011).Clinical presentation and management of handfoot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Oncologist,16,1508-1519.
15. Guttman-Yassky, E.(2010).Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.Eur. J. Cancer,46,2010-2019.
16. Hu, J. C.,Sadeghi, P.,Pinter-Brown, L. C.,Yashar, S.,Chiu, M. W.(2007).Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.J. Am. Acad. Dermatol,56,317-326.
17. Jatoi, A.,Green, E. M.,Rowland, K. M., Jr.,Sargent, D. J.,Alberts, S. R.(2009).Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.Oncology,77,120-123.
18. Kong, H. H.,Fine, H. A.,Stern, J. B.,Turner, M. L.(2009).Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.Arch. Dermatol,145,923-925.
19. Lacouture, M. E.(2013).Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev.Anticancer Ther,13,721-728.
20. Lacouture, M. E.(2013).Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients.WileyBlackwell.
21. Lacouture, M. E.(2011).Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Support Care Cancer,19,1079-1095.
22. Lacouture, M. E.(2006).Mechanisms of cutaneous toxicities to EGFR inhibitors.Nat. Rev. Cancer,6,803-812.
23. Lacouture, M. E. & Belum, V. R. Dermatologic Adverse Events Associated With Systemic Anticancer Agents (2014).
24. Lacouture, M. E.,Reilly, L. M.,Gerami, P.,Guitart, J(2008).Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.Ann. Oncol.,19,1955-1961.
25. Li, T.,Perez-Soler, R.(2009).Skin toxicities associated with epidermal growth factor receptor inhibitors.Target. Oncol,4,107-119.
26. Lipworth, A. D.,Robert, C.,Zhu, A.(2009).Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.Oncology,77,257-271.
27. LoRusso, P(2009).Toward e vidence-based management of the dermatologic effects of EGFR inhibitors.Oncology,23,186-194.
28. Lynch, T. J., Jr.(2007).Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.Oncologist,12,610-621.
29. Melosky, B.(2009).Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.Curr. Oncol.,16,16-26.
30. Multinational Association of Supportive Care in Cancer. MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT©), (2011).
31. Osio, A.(2009).Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.Br. J. Dermatol,161,515-521.
32. Pass, H. I.,Ball, D.,Scagliotta, G. V.(2013).The IASLC Multidisciplinary Approach to Thoracic Oncology.International Association for the Study of Lung Cancer.
33. Peeters, M.(2009).Association of progressionfree survival, overall survival, and patientreported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.Cancer,115,1544-1554.
34. Perez-Soler, R.(2004).Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.J. Clin. Oncol,22,3238-3247.
35. Peuvrel, L.(2012).Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.Support Care Cancer,20,909-921.
36. Potthoff, K.(2011).Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.Ann. Oncol,22,524-535.
37. Robert, C.(2005).Cutaneous side-effects of kinase inhibitors and blocking antibodies.Lancet Oncol,6,491-500.
38. Roe, E.(2006).Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.J. Am. Acad. Dermatol,55,429-437.
39. Segaert, S.,Van Cutsem, E.(2005).Clinical signs athophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.Ann. Oncol.,16,1425-1433.
40. Son, Y. M.,Roh, J. Y.,Cho, E. K.,Lee, J. R(2011).Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel.Annals of dermatology,23,S314-S318.
41. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health & National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, (2010).
42. U.S. Food and Drug Administration.,未出版
43. Ulrich, J.,Hartmann, J. T.,Dorr, W.,Ugurel, S.(2008).Skin toxicity of anti-cancer therapy.Journal of the German Society of Dermatology,6,959-977.
44. Walko, C. M.,Grande, C.(2014).Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.Semin. Oncol,41(Suppl 2),S17-S28.
45. Wheatley-Price, P.,Ding, K.,Seymour, L.,Clark, G. M.,Shepherd, F. A.(2008).Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.J. Clin. Oncol.,26,2350-2357.
46. Wollenberg, A.,Kroth, J.,Hauschild, A.,Dirschka, T.(2010).Cutaneous side effects of EGFR inhibitors--appearance and management.Dtsch. Med Wochenschr,135,149-154.
47. 衛生福利部食品藥物管理署．衛生福利部食品藥物管理署西藥、醫療器材、含藥化妝品許可證查詢。(2014).

1. 林芷亘(2017)。晚期非小細胞肺癌病人於首療標靶藥物期間生活品質之縱貫性研究。長榮大學醫務管理學系(所)學位論文。2017。1-150。